BIOVAXYS
BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is... a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
BIOVAXYS
Industry:
Biopharma Biotechnology
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.biovaxys.com
Total Employee:
1+
Status:
Active
Contact:
610 977 2440
Email Addresses:
[email protected]
Total Funding:
4.94 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-08 | BioVaxys Announces New Chief Financial Officer |
Official Site Inspections
http://www.biovaxys.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "BioVaxys"
BioVaxys - Crunchbase Company Profile & Funding
BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine âŠSee details»
Meet the Leaders - BioVaxys Technology Executive Team and âŠ
Mr. James Passin is a former hedge fund and private equity fund manager at New York-based Firebird Management LLC. He has 20 years of experience as a professional investor, a deep âŠSee details»
BioVaxys Technology Corp. - LinkedIn
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with ...See details»
Investor Relations - BioVaxys Financial Insights and âŠ
BioVaxys Technology Corp, having acquired IMV INC, invites investors to join our mission in reshaping the future of antiviral and cancer treatments. Discover âŠSee details»
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL âŠ
Feb 21, 2024 At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of âŠSee details»
BioVaxys Technology Corp. - Canadian Securities Exchange
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX⢠immune-educating technology âŠSee details»
BioVaxys Technology (BVAXF) Company Profile & Description
Apr 21, 2025 BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers âŠSee details»
Biovaxys Technology (BVAXF) Company Profile, History, Products âŠ
BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-11-21. The firm is âŠSee details»
BioVaxys Company Profile - Office Locations, Competitors ... - Craft
BioVaxys. Stock Price. $0.1. 2024-10-29. Market Capitalization. $14.5 M. 2024-10-29. BioVaxys Summary. Company Summary. Overview. BioVaxys is a clinical-stage biopharma developing âŠSee details»
BioVaxys Technology Corp. Granted Management Cease Trade âŠ
Mar 3, 2025 BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company âŠSee details»
BioVaxys - Funding, Financials, Valuation & Investors - Crunchbase
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma. New. Resources. Advanced Search. ... Which types of âŠSee details»
BioVaxys Technology Company Description - Stock Analysis
Mar 20, 2025 BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers âŠSee details»
Pharma's Almanac: Nice Insight's Content Community
Jan 17, 2025 BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies âŠSee details»
Contact us - BioVaxys
[email protected] +1 740 358 0555. 146 Thirtieth Street. Suite 100. Etobicoke, Ontario. Canada. 1801 NE 123rd Street, Suite 314. North Miami, FL 33181 USA. First name. Last âŠSee details»
BioVaxys Technology Corp. to Present at the Emerging Growth
Jan 14, 2025 BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies âŠSee details»
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into ...
Apr 22, 2025 BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies âŠSee details»
BioVaxys Executes Letter of Intent for Major Immunotherapeutics ...
VANCOUVER, BC, Dec. 22, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non âŠSee details»
BioVaxys Shares New Data on its DPX⢠Immune Educating âŠ
Dec 5, 2024 BioVaxys Technology Corp. (www.biovaxys.com)is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies âŠSee details»
Who Owns BioVaxys â CanvasBusinessModel.com
Oct 2, 2024 Ownership drives innovation, fosters a culture of dedication and commitment, empowers employees to think creatively, and cultivates pride and loyalty. By embracing âŠSee details»
BioVaxys Shares New Data on its DPX⢠Immune Educating
Dec 5, 2024 BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies âŠSee details»